Immune response to SARS-CoV-2 mRNA vaccine in patients with psoriasis treated with biologics

Maruška Marovt; Petra Deželak; Robert Ekart; Pij B Marko

doi:10.1111/ced.15347

Immune response to SARS-CoV-2 mRNA vaccine in patients with psoriasis treated with biologics

Clin Exp Dermatol. 2022 Nov;47(11):2041-2043. doi: 10.1111/ced.15347. Epub 2022 Aug 27.

Authors

Maruška Marovt¹, Petra Deželak², Robert Ekart³, Pij B Marko¹

Affiliations

¹ Department of Dermatovenerology, University Medical Centre Maribor, Ljubljanska, Maribor, Slovenia.
² National Laboratory of Health, Environment and Food, Maribor, Slovenia.
³ Department of Dialysis, Clinic for Internal Medicine, University Medical Centre Maribor, Ljubljanska, Maribor, Slovenia.

Abstract

The effect of psoriasis treatment with biologics on the efficacy of COVID-19 vaccines is largely unknown. Our study aimed to evaluate antibody response against SARS-CoV-2 following two doses of BNT162b2 (Pfizer/BioNTech vaccine) in patients with psoriasis receiving biologic monotherapy, and compare it with that of healthy controls.

Publication types

Letter

MeSH terms

Animals
Antibodies, Viral
BNT162 Vaccine
COVID-19 Vaccines / therapeutic use
COVID-19* / prevention & control
Humans
Immunity
Mice
Mice, Inbred BALB C
Psoriasis* / drug therapy
SARS-CoV-2
Viral Vaccines*
mRNA Vaccines

Substances

COVID-19 Vaccines
Viral Vaccines
BNT162 Vaccine
Antibodies, Viral

Grants and funding

Univerzitetni Klinini Center Maribor